Rheumatoid Arthritis
|
0.100 |
GeneticVariation
|
disease |
GWASDB |
TRAF1-C5 as a risk locus for rheumatoid arthritis--a genomewide study.
|
17804836 |
2007 |
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
GeneticVariation
|
disease |
GWASDB |
A genome-wide association study identifies KIAA0350 as a type 1 diabetes gene.
|
17632545 |
2007 |
Multiple Sclerosis
|
0.100 |
GeneticVariation
|
disease |
GWASDB |
Risk alleles for multiple sclerosis identified by a genomewide study.
|
17660530 |
2007 |
Psoriasis
|
0.130 |
GeneticVariation
|
disease |
GWASDB |
A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci.
|
18369459 |
2008 |
Psoriasis
|
0.130 |
GeneticVariation
|
disease |
GWASCAT |
A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci.
|
18369459 |
2008 |
Psoriasis
|
0.130 |
GeneticVariation
|
disease |
BEFREE |
However, rs2395029 encoding the G2V polymorphism within the class I gene HCP5 (combined P = 2.13x10(-26) in U.S. cases) yielded the highest ORs with both PS and PSA (4.1 and 3.2 respectively).
|
18369459 |
2008 |
HIV Infections
|
0.040 |
Biomarker
|
group |
BEFREE |
They specifically demonstrate that the influence of ZNRD1 alleles on disease progression rates are attributable to HLA-A10, help clarify the relationship between the HCP5, HLA-C and HLA-B*57 alleles, and reaffirm a critical role of HLA-B*57 alleles in HIV disease.
|
18982067 |
2008 |
Progressive Neoplastic Disease
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
Furthermore, HCP5 and HLA-C alleles stratify B*57-containing genotypes into those that associate with either striking disease retardation or progressive disease, providing one explanation for the long-standing conundrum of why some HLA-B*57-carrying individuals are long-term non-progressors, whereas others exhibit progressive disease.
|
18982067 |
2008 |
Salivary Gland Pleomorphic Adenoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
However, rs2395029 encoding the G2V polymorphism within the class I gene HCP5 (combined P = 2.13x10(-26) in U.S. cases) yielded the highest ORs with both PS and PSA (4.1 and 3.2 respectively).
|
18369459 |
2008 |
Progressive cGVHD
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, HCP5 and HLA-C alleles stratify B*57-containing genotypes into those that associate with either striking disease retardation or progressive disease, providing one explanation for the long-standing conundrum of why some HLA-B*57-carrying individuals are long-term non-progressors, whereas others exhibit progressive disease.
|
18982067 |
2008 |
Human immunodeficiency virus (HIV) II infection category B1
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
This study of 1,103 individuals infected with human immunodeficiency virus assessed the usefulness of genotyping a HCP5 single-nucleotide polymorphism (SNP), rs2395029, in relation to ABC-HSR.
|
18684101 |
2008 |
Acquired Immunodeficiency Syndrome
|
0.100 |
GeneticVariation
|
group |
GWASDB |
Genomewide association study of an AIDS-nonprogression cohort emphasizes the role played by HLA genes (ANRS Genomewide Association Study 02).
|
19115949 |
2009 |
Acquired Immunodeficiency Syndrome
|
0.100 |
GeneticVariation
|
group |
GWASCAT |
Genomewide association study of an AIDS-nonprogression cohort emphasizes the role played by HLA genes (ANRS Genomewide Association Study 02).
|
19115949 |
2009 |
Rheumatoid Arthritis
|
0.100 |
GeneticVariation
|
disease |
GWASDB |
REL, encoding a member of the NF-kappaB family of transcription factors, is a newly defined risk locus for rheumatoid arthritis.
|
19503088 |
2009 |
HUMAN IMMUNODEFICIENCY VIRUS TYPE 1, SUSCEPTIBILITY TO
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Common genetic variation and the control of HIV-1 in humans.
|
20041166 |
2009 |
HUMAN IMMUNODEFICIENCY VIRUS TYPE 1, SUSCEPTIBILITY TO
|
0.100 |
GeneticVariation
|
disease |
GWASDB |
Common genetic variation and the control of HIV-1 in humans.
|
20041166 |
2009 |
HIV-1, RESISTANCE TO
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Common genetic variation and the control of HIV-1 in humans.
|
20041166 |
2009 |
HIV-1, RESISTANCE TO
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Common genetic variation and the control of HIV-1 in humans.
|
20041166 |
2009 |
ACQUIRED IMMUNODEFICIENCY SYNDROME, PROGRESSION TO
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Common genetic variation and the control of HIV-1 in humans.
|
20041166 |
2009 |
ACQUIRED IMMUNODEFICIENCY SYNDROME, PROGRESSION TO
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Common genetic variation and the control of HIV-1 in humans.
|
20041166 |
2009 |
AIDS, PROGRESSION TO
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Common genetic variation and the control of HIV-1 in humans.
|
20041166 |
2009 |
AIDS, PROGRESSION TO
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Common genetic variation and the control of HIV-1 in humans.
|
20041166 |
2009 |
Chemical and Drug Induced Liver Injury
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin.
|
19483685 |
2009 |
Chemical and Drug Induced Liver Injury
|
0.100 |
GeneticVariation
|
disease |
GWASDB |
HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin.
|
19483685 |
2009 |
HIV Infections
|
0.040 |
GeneticVariation
|
group |
BEFREE |
A genome-wide association study of people with incident human immunodeficiency virus (HIV) infection selected from nine different cohorts identified allelic polymorphisms, which associated with either viral set point (HCP5 and 5' HLA-C) or with HIV disease progression (RNF39 and ZNRD1).
|
19693088 |
2009 |